KD
Therapeutic Areas
Brii Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | COVID-19 | Approved |
| BRII-835 (VIR-2218) + BRII-179 (VBI-2601) | Chronic Hepatitis B | Phase 2 |
| BRII-179 (VBI-2601) | Chronic Hepatitis B | Phase 2a/2b |
| VIR-3434 | Chronic Hepatitis B | Preclinical/Phase 1 (ex-China) |
| BRII-732 | HIV (PrEP) | Phase 1 |
| BRII-296 | Postpartum Depression | Phase 1 |
Leadership Team at Brii Biosciences
ZH
Zhi Hong
Co-Founder, Chairman & CEO
SC
Susannah Cantrell
Chief Business Officer
ED
Eleanor de Groot
Chief Technology Officer
AS
Aleksandar Skuban
CNS Diseases Therapy Area Head
CS
Coy Stout
SVP, Head of U.S. Market Access & Patient Advocacy
TY
Taiyin Yang
Board Director